MedDRA preferred term · the device blocked

Device occlusion: adverse event reports recording this term

13,725 reports to FDA record it, 2005–2026; 0.1% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

13,725
reports recording the term: 0.1% of all reports; 1,148
reports, 12 months to June 2026: 1,932 in the 12 months before; 40.4%
marked serious by the reporter: 57.4% across all reports; 3.8%
record death among outcomes, as reported: 9.1% across all reports

13,725 reports in FDA's adverse event database record the MedDRA term "Device occlusion" (in plain words, the device blocked): 0.1% of all reports received between December 2005 and June 2026. Coders pick the term that best matches the reporter's description.

1,148 reports recorded it in the 12 months to June 2026, down 41% from 1,932 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 40.4% are marked serious, 3.8% include death among the outcomes and 28% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Neulasta, Eligard and Genotropin. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Neulasta	Leukocyte growth factor	3,253	4%
Eligard	Gonadotropin releasing hormone receptor agonist	903	2%
Genotropin	—	706	1.6%
Carbidopa levodopa	Aromatic amino acid	536	2.7%
Duodopa	—	533	3.1%
Remodulin	Prostacycline vasodilator	511	1.1%
Duopa	Aromatic amino acid	443	5.2%
Albuterol sulfate	beta2-Adrenergic agonist	367	0.8%
Veletri	Prostacycline vasodilator	325	3.7%
Device	—	283	5.6%
Inbrija	Aromatic amino acid	232	4%
Epoprostenol sodium	—	199	11.1%
Risperdal Consta	—	192	1.4%
Depo-Provera	Progestin	141	0.8%
Brilinta	P2Y12 platelet inhibitor	140	0.8%
Medroxyprogesterone	Progestin	133	4.4%
Ryaltris	Corticosteroid	133	7.7%
Lioresal (baclofen)	gamma-Aminobutyric acid-ergic agonist	125	1.1%
Baclofen	gamma-Aminobutyric acid-ergic agonist	119	0.5%
Opsumit	Endothelin receptor antagonist	117	0.3%
Albuterol	beta2-Adrenergic agonist	96	0.5%
Humira	—	85	0%
Omnitrope	Recombinant human growth hormone	84	0.7%
Flolan	—	76	1.7%
Effient	P2Y12 platelet inhibitor	75	1.3%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0.1% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Leukocyte growth factor	3,338	3.1%	0%
Aromatic amino acid	1,227	2.3%	0.1%
Gonadotropin releasing hormone receptor agonist	925	1.5%	0%
Prostacycline vasodilator	890	0.7%	0.3%
beta2-Adrenergic agonist	465	0.5%	0%
gamma-Aminobutyric acid-ergic agonist	308	0.9%	1.1%
P2Y12 platelet inhibitor	298	0.3%	0.2%
Endothelin receptor antagonist	291	0.2%	0.2%
Progestin	283	0.1%	0%
Corticosteroid	209	0%	0%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20.4%50

2 to 112.9%404

12 to 172.8%391

18 to 448.8%1,203

45 to 6421%2,881

65 to 7417.3%2,371

75 and over12.1%1,662

Age not given34.7%4,763

Patient sex

Female41.9%5,748

Male42.4%5,822

Not given15.7%2,155

Grey bar: all 20,646,523 reports in the database. 67.9% of these reports give the United States as the country.

Questions about "Device occlusion"

What does "Device occlusion" mean in an adverse event report?

In plain language: the device blocked. It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record device occlusion?

13,725 reports through June 2026 (0.1% of all reports), 1,148 of them in the latest 12 months.

Which drugs appear most often in these reports?

Neulasta (3,253), Eligard (903), Genotropin (706), Carbidopa levodopa (536) and Duodopa (533). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.